Scisparc Ltd
NASDAQ:SPRC
Scisparc Ltd
NASDAQ:SPRC
Price:
4.23
USD
-4.3%
Market Closed
Market Cap:
$2.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Natural Food International Holding Ltd
HKEX:1837
|
CN |
|
Cenkos Securities PLC
LSE:CNKS
|
UK |
Scisparc Ltd
Capital Expenditures
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Scisparc Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Capital Expenditures
-$9.8m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Capital Expenditures
-$95k
|
CAGR 3-Years
76%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-12%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Capital Expenditures
-$289k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Capital Expenditures
-$83k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Capital Expenditures
-$1.9m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-1%
|
|
No Stocks Found
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
SPRC
Intrinsic Value
12.48
USD
Undervaluation 66%
